A Phase 2 interventional study of PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430) in Constipation, sponsored by Bayer. Completed at 1 site in Ireland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-15.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing polyethylene glycol 3350 in Constipation — 3 open to participants now, 4 under way, none of them phase 3. polyethylene glycol 3350 · Constipation.
Among the 27 studies testing polyethylene glycol 3350 in Constipation, this one is the 9th largest by enrollment, is one of 2 that started in 2010, is one of 2 in phase 2, and was the 13th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →3 of the 27 studies testing polyethylene glycol 3350 in Constipation are open now, in 2 countries. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 2–18 · Healthy volunteers
Chad R. Tracy · Sites in United States
Ages 30–100 · Healthy volunteers
Shaare Zedek Medical Center · Sites in Israel
Ages 4–17
By country, each count listing its studies:
polyethylene glycol 3350: first FDA approval 1984 (GOLYTELY). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 100 across the 27 interventional studies. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 27 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 6 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
2 of the studies testing polyethylene glycol 3350 in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05821309Indiana UniversityEvaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen | 2027-07 |
| NCT07604025Shaare Zedek Medical CenterSenna vs. Polyethylene Glycol 3350 for the Treatment of Retentive Encopresis in Children | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing polyethylene glycol 3350 in Constipation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to evaluate the proportion of subjects with a bowel movement (BM) without straining or without hard and/or lumpy stool within the first 24 h of treatment for subjects taking 1 of 3 single doses of Polyethylene Glycol (PEG) plus Electrolytes (PEG+E) (13.125 g, 26.25 g, 39.375 g). The doses specified relate to the doses of PEG. Secondary objectives were measured by analysis of a subject diary and self-reported BM data. The secondary objectives included comparisons of PEG+E doses at 24 h for: BM control; relief of gas; relief of bloating; and relief of abdominal discomfort/cramping.
In addition, the proportion of subjects with a BM (without straining and without hard and/or lumpy stool) within the first 24 h of treatment for subjects taking different doses of PEG+E was evaluated for the time to first BM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time
Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time
Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
Three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time
Drug: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
Drug pages: Polyethylene glycol 3350 · Electrolytes · Polyethylene Glycols
13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration
A successful BM was defined as a BM with no straining or hard/lumpy stools.
Time frame: From time of study drug treatment up to 24 hours
Number of Participants With Time To First Successful BM In 0 Days Through 0.5 Days, >0.5 Days Through 1.0 Days, or >1.0 Days Through 1.5 Days After PEG+E Administration
Time to first successful bowel movement was defined as the duration (in days) from the time of first study dose of study treatment until first successful BM (defined as BM without straining and without hard and/or lumpy stool).
Time frame: From time of study drug administration up to 3 Days
Percentage of Participants With Successful BM Within 12 Hours of PEG+E Administration
A successful BM was defined as a BM with no straining or hard/lumpy stools.
Time frame: From time of study drug treatment up to 12 hours
Mean Visual Analog Scale (VAS) Rating for BM Control
The VAS is a psychometric response scale which measures responses along a continuum of values. The BM control VAS uses a 100 mm horizontal line with the two ends representing the opposite, extreme limits of the participant's experience of BM control. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. BM Control ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=Calm, not urgent and 100 mm= Not able to hold BM, very urgent. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group
Time frame: From time of study drug treatment up to 24 hours
Mean VAS Rating for Gas
The VAS is a psychometric response scale which measures responses along a continuum of values. The Gas VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related gas. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Gas ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.
Time frame: From time of study drug treatment up to 24 hours
Mean VAS Rating for Bloating
The VAS is a psychometric response scale which measures responses along a continuum of values. The Bloating VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related bloating. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Bloating ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.
Time frame: From time of study drug treatment up to 24 hours
Mean VAS Rating for Abdominal Discomfort/Cramping
The VAS is a psychometric response scale which measures responses along a continuum of values. The Abdominal Discomfort/Cramping VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related abdominal discomfort/cramping. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Abdominal discomfort/cramping ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Painful. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.
Time frame: From time of study drug treatment up to 24 hours
Mean Participant Global Assessment of Treatment
At the End of Study Visit, the study staff asked the participant to rate their global assessment of the study treatment according to the following categories: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective.
Time frame: From time of study drug administration up to 2 Days
| Milestone | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g |
|---|---|---|---|
| Started | 52 | 51 | 51 |
| Completed | 52 | 51 | 51 |
| Not completed | 0 | 0 | 0 |
A successful BM was defined as a BM with no straining or hard/lumpy stools.
| percentage of participants | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g |
|---|---|---|---|
| Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration | 19.2 | 31.4 | 19.2 |
Time to first successful bowel movement was defined as the duration (in days) from the time of first study dose of study treatment until first successful BM (defined as BM without straining and without hard and/or lumpy stool).
| participants | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g |
|---|---|---|---|
| Successful BM in 0 days through 0.5 days | 4 | 8 | 6 |
| Successful BM in >0.5 days through 1.0 days | 6 | 8 | 4 |
| Successful BM in >1.0 days through 1.5 days | 1 | 0 | 2 |
A successful BM was defined as a BM with no straining or hard/lumpy stools.
| percentage of participants | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g |
|---|---|---|---|
| Percentage of Participants With Successful BM Within 12 Hours of PEG+E Administration | 7.7 | 15.7 | 11.8 |
The VAS is a psychometric response scale which measures responses along a continuum of values. The BM control VAS uses a 100 mm horizontal line with the two ends representing the opposite, extreme limits of the participant's experience of BM control. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. BM Control ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=Calm, not urgent and 100 mm= Not able to hold BM, very urgent. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group
| mm | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g |
|---|---|---|---|
| Mean Visual Analog Scale (VAS) Rating for BM Control | 31.1 ± 27.27 | 23.5 ± 23.76 | 29.4 ± 23.59 |
The VAS is a psychometric response scale which measures responses along a continuum of values. The Gas VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related gas. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Gas ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.
| mm | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g |
|---|---|---|---|
| Mean VAS Rating for Gas | 23.9 ± 21.87 | 25.4 ± 27.14 | 26.0 ± 22.93 |
The VAS is a psychometric response scale which measures responses along a continuum of values. The Bloating VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related bloating. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Bloating ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.
| mm | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g |
|---|---|---|---|
| Mean VAS Rating for Bloating | 33.9 ± 32.39 | 21.7 ± 25.10 | 32.7 ± 29.55 |
The VAS is a psychometric response scale which measures responses along a continuum of values. The Abdominal Discomfort/Cramping VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related abdominal discomfort/cramping. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Abdominal discomfort/cramping ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Painful. Participants completed a VAS after every BM or attempted BM. The VAS ratings recorded in the diaries for each BM were averaged (with range) to yield a single score for each participant. Participant scores were then averaged by treatment group.
| mm | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g |
|---|---|---|---|
| Mean VAS Rating for Abdominal Discomfort/Cramping | 17.4 ± 24.91 | 14.0 ± 22.56 | 14.5 ± 16.89 |
At the End of Study Visit, the study staff asked the participant to rate their global assessment of the study treatment according to the following categories: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective.
| units on a scale | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g |
|---|---|---|---|
| Mean Participant Global Assessment of Treatment | 1.0 ± 1.15 | 1.3 ± 1.26 | 1.2 ± 1.20 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG + E 13.125 g | — | 0/52 (0%) | 0/52 (0%) |
| PEG + E 26.25 g | — | 0/51 (0%) | 0/51 (0%) |
| PEG + E 39.375 g | — | 0/51 (0%) | 0/51 (0%) |
| Age, Continuous(years) | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g | Total |
|---|---|---|---|---|
| Mean | 45.9 ± 16.31 | 50.4 ± 14.27 | 43.3 ± 13.8 | 46.5 ± 14.85 |
| Sex: Female, Male(Participants) | PEG + E 13.125 g | PEG + E 26.25 g | PEG + E 39.375 g | Total |
|---|---|---|---|---|
| Female | 48 | 44 | 41 | 133 |
| Male | 4 | 7 | 10 | 21 |
The record gives a start of Oct 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Polyethylene glycol 3350 · Electrolytes · Polyethylene Glycols